Castle Biosciences, Inc. (CSTL)
Automate Your Wheel Strategy on CSTL
With Tiblio's Option Bot, you can configure your own wheel strategy including CSTL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CSTL
- Rev/Share 12.132
- Book/Share 15.3905
- PB 1.0364
- Debt/Equity 0.0587
- CurrentRatio 9.3735
- ROIC -0.0675
- MktCap 460513185.0
- FreeCF/Share 1.4594
- PFCF 11.03
- PE -90.0204
- Debt/Assets 0.0515
- DivYield 0
- ROE -0.0115
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City.
Read More
Castle Biosciences Celebrates Skin Cancer Awareness Month
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
Read More
Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Matthew Goldberg - Senior Vice President, Medical Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Puneet Souda - Leerink Partners Tom Peterson - Baird Paul Knight - KeyBanc Capital Markets Subbu Nambi - Guggenheim Mason Carrico - Stephens Thomas Flaten - Lake Street Mark Massaro - BTIG Operator Good afternoon and welcome …
Read More
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage I-III cutaneous melanoma.
Read More
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Consistent with prior studies, published results from Castle's DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression 1,2 As of the last follow-up, all of the patients in the third study analysis with a low-risk DecisionDx-Melanoma test result (Class 1A) were recurrence free, regardless of SLN status 3 FRIENDSWOOD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative …
Read More
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Subbu Nambi - Guggenheim Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Paul Knight - KeyBanc Mason Carrico - Stephens Tom Peterson - Baird Vidyun Bais - BTIG Kyle Mikson - Canaccord Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2024 Conference Call. As a reminder, today's call is being recorded.
Read More
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
Read More
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of GEP tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, Feb. 14-19.
Read More
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Castle Biosciences, Inc. (CSTL)
- IPO Date 2019-07-25
- Website https://castlebiosciences.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Derek J. Maetzold
- Employees 784